OpenURL Connection Search

Select item for more details and to access through your institution.

<sup>18</sup>F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.
Published in:
Bone Marrow Transplantation, 2014, v. 49, n. 1, p. 131, doi. 10.1038/bmt.2013.144
By:
- Bodet-Milin, C;
- Lacombe, M;
- Malard, F;
- Lestang, E;
- Cahu, X;
- Chevallier, P;
- Guillaume, T;
- Delaunay, J;
- Brissot, E;
- Moreau, P;
- Kraeber-Bodere, F;
- Mohty, M
Publication type:
Article
Impact of high-dose chemotherapy followed by auto-SCT for positive interim [<sup>18</sup>F] FDG-PET diffuse large B-cell lymphoma patients.
Published in:
Bone Marrow Transplantation, 2011, v. 46, n. 3, p. 393, doi. 10.1038/bmt.2010.130
By:
- Roland, V.;
- Bodet-Milin, C.;
- Moreau, A.;
- Gastinne, T.;
- Mahé, B.;
- Dubruille, V.;
- Maisonneuve, H.;
- Juge-Morineau, N.;
- Moreau, P.;
- Jardel, H.;
- Planche, L.;
- Mohty, M.;
- Harousseau, J.-L.;
- Kraeber-Bodéré, F.;
- Le Gouill, S.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas1-, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas1-, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study. .
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post-hoc analysis of the iPET-MTC study.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 37, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post-hoc analysis of the iPET-MTC study.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post-hoc analysis of the iPET-MTC study.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.252791
By:
- Bodet-Milin, C.;
- Faivre-Chauvet, A.;
- Carlier, T.;
- Ansquer, C.;
- Rauscher, A.;
- Frampas, E.;
- Toulgoat, F.;
- Masson, D.;
- Bourgeois, M.;
- Cerato, E.;
- Rohmer, V.;
- Couturier, O.;
- Drui, D.;
- Goldenberg, D. M.;
- Sharkey, R. M.;
- Barbet, J.;
- Kraeber-Bodere, F.
Publication type:
Article
Predictive value of FDG‐PET imaging for relapse in metastatic melanoma patients treated with immunotherapy.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2020, v. 34, n. 10, p. 2261, doi. 10.1111/jdv.16358
By:
- Mesnard, C.;
- Bodet‐Milin, C.;
- Eugène, T.;
- Nguyen, J‐M.;
- Khammari, A.;
- Dréno, B.
Publication type:
Article
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination.
Published in:
Hematological Oncology, 2023, v. 41, p. 478, doi. 10.1002/hon.3164_352
By:
- Le Gouill, S.;
- Morschhauser, F.;
- Chiron, D.;
- Bouabdallah, K.;
- Cartron, G.;
- Casasnovas, O.;
- Rule, S.;
- Bodet‐Milin, C.;
- Herbaux, C.;
- Gastinne, T.;
- Callanan, M.;
- Tessoulin, B.
Publication type:
Article
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 44, doi. 10.1002/hon.14_2629
By:
- Le Gouill, S.;
- Beldi‐Ferchiou, A.;
- Cacheux, V.;
- Salles, G.;
- Canioni, D.;
- Bodet‐Milin, C.;
- Alcantara, M.;
- Delwail, V.;
- Gastinne, T.;
- Thieblemont, C.;
- Maisonneuve, H.;
- Lamy de la Chapelle, T.;
- Oberic, l.;
- Bouabdallah, K.;
- Ribrag, V.;
- Delfau‐Larue, M.;
- Macintyre, E.;
- Hermine, O.
Publication type:
Article
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 44, doi. 10.1002/hon.14_2629
By:
- Le Gouill, S.;
- Beldi‐Ferchiou, A.;
- Cacheux, V.;
- Salles, G.;
- Canioni, D.;
- Bodet‐Milin, C.;
- Alcantara, M.;
- Delwail, V.;
- Gastinne, T.;
- Thieblemont, C.;
- Maisonneuve, H.;
- Lamy de la Chapelle, T.;
- Oberic, l.;
- Bouabdallah, K.;
- Ribrag, V.;
- Delfau‐Larue, M.;
- Macintyre, E.;
- Hermine, O.
Publication type:
Article
Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
Published in:
2010
By:
- Ferrer L;
- Kraeber-Bodéré F;
- Bodet-Milin C;
- Rousseau C;
- Le Gouill S;
- Wegener WA;
- Goldenberg DM;
- Bardiès M
Publication type:
Journal Article
Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
Published in:
2010
By:
- Salaun PY;
- Bodet-Milin C;
- Frampas E;
- Oudoux A;
- Saï-Maurel C;
- Faivre-Chauvet A;
- Barbet J;
- Paris F;
- Kraeber-Bodéré F
Publication type:
Journal Article
FDG-PET in Follicular Lymphoma Management.
Published in:
Journal of Oncology, 2012, p. 1, doi. 10.1155/2012/370272
By:
- Bodet-Milin, C.;
- Eugène, T.;
- Gastinne, T.;
- Frampas, E.;
- Le Gouill, S.;
- Kraeber-Bodéré, F.
Publication type:
Article
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 3, p. 874, doi. 10.1007/s00259-020-04989-3
By:
- Touchefeu, Y.;
- Bailly, C.;
- Frampas, E.;
- Eugène, T.;
- Rousseau, C.;
- Bourgeois, M.;
- Bossard, C.;
- Faivre-Chauvet, A.;
- Rauscher, A.;
- Masson, D.;
- David, A.;
- Cerato, E.;
- Carlier, T.;
- Sharkey, R. M.;
- Goldenberg, D. M.;
- Barbet, J.;
- Kraeber-Bodere, F.;
- Bodet-Milin, C.
Publication type:
Article

Found: 18